Positive Phase III data for risankizumab induction in patients with Crohn’s disease

In ADVANCE (patients with inadequate response or intolerant to conventional and/or biologic therapy) and MOTIVATE (inadequate response or intolerant to biologic therapy), both 600mg and 1200mg doses met primary endpoints of clinical remission and endoscopic response at week 12.

Source:

Biospace Inc.